TTM
$0.00
YoY change
—
5Y CAGR
—
Peak year (2012)
$2.14K
Cumulative gross profit
−$153.61K
Gross Profit history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: $0.00
Gross Profit growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: -100.0%
Gross Profit history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | $0.00 | — | $0.00 | ||
| 2024 | $0.00 | — | $0.00 | ||
| 2023 | $0.00 | — | $0.00 | ||
| 2022 | $0.00 | — | $0.00 | ||
| 2021 | $0.00 | — | $0.00 | ||
| 2020 | $0.00 | — | $0.00 | ||
| 2019 | $0.00 | -100.0% | +$4.87K | ||
| 2018 | −$4.87K | +85.4% | −$2.24K | ||
| 2017 | −$2.63K | -96.9% | +$82.64K | ||
| 2016 | −$85.27K | +55.6% | −$30.45K | ||
| 2015 | −$54.82K | +492.3% | −$45.56K | ||
| 2014 | −$9.26K | -946.8% | −$10.35K | ||
| 2013 | $1.09K | -49.0% | −$1.05K | ||
| 2012 | $2.14K | — | — |
- 2025$0.00—
- 2024$0.00—
- 2023$0.00—
- 2022$0.00—
- 2021$0.00—
- 2020$0.00—
- 2019$0.00-100.0%
- 2018−$4.87K+85.4%
- 2017−$2.63K-96.9%
- 2016−$85.27K+55.6%
- 2015−$54.82K+492.3%
- 2014−$9.26K-946.8%
- 2013$1.09K-49.0%
- 2012$2.14K—
Gross Profit values are taken from Relmada Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Gross Profit at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's current gross profit (TTM) is $0.00. Gross profit equals revenue minus the cost of goods sold (COGS) — what remains from sales after the direct cost of producing the product or service. It does not yet subtract operating expenses, interest, or taxes (see operating income and net income for those steps). Higher gross profit (and gross margin) generally signals pricing power and production efficiency.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Relmada Therapeutics (RLMD) most recent annual gross profit stands at $0.00 (2025).
Relmada Therapeutics gross profit peaked at $2.14K in 2012; the latest annual figure is $0.00 in 2025 (100.0% below peak).
2012 marks the peak gross profit at $2.14K, with the historical low of −$85.27K recorded in 2016.
Relmada Therapeutics Gross Profit by Year
Relmada Therapeutics Gross Profit 2025: $0.00
Relmada Therapeutics gross profit in 2025 was $0.00.
Relmada Therapeutics Gross Profit 2024: $0.00
Relmada Therapeutics gross profit in 2024 was $0.00.
Relmada Therapeutics Gross Profit 2023: $0.00
Relmada Therapeutics gross profit in 2023 was $0.00.
Relmada Therapeutics Gross Profit 2022: $0.00
Relmada Therapeutics gross profit in 2022 was $0.00.
Relmada Therapeutics Gross Profit 2021: $0.00
Relmada Therapeutics gross profit in 2021 was $0.00.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Gross Profit
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest gross profit
| $82.92B | |
| $68.56B | |
| $54.62B | |
| $48.11B | |
| $46.73B | |
| $42.96B | |
| $39.01B | |
| $26.01B |
- $82.92B
- $68.56B
- $54.62B
- $48.11B
- $46.73B
- $42.96B
- $39.01B
- $26.01B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation